|
COPYRIGHT 2005 Asia Pulse Pty Ltd
to over 380,000 people in Europe this year who have received the devastating news that they have lung cancer.
Not only has Tarceva demonstrated a striking survival benefit (42.5 percent) in advanced non-small cell lung cancer, the most common form of the disease, it has also been shown to significantly improve patients' quality of life by alleviating the severe and debilitating symptoms that characterise advanced disease, such as cough, pain and breathlessness.
June Sheldon, a 71 year old grandmother, was diagnosed with advanced non-small cell lung cancer April 2002.
"I could hardly breathe before and didn't think I would last a year. I'm living proof of the benefit of taking Tarceva, I don't think I would be here otherwise and it made a difference to my life much more quickly than I thought," said June. "Now I go out for lunch two or three times a week and wander around the shops, I really feel I can get on with my life."
Physicians and patients are crying out for new lung cancer treatments as globally the disease is increasing at such an alarming rate that it is often referred to as an epidemic.(1) The highest rates are seen in...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
